Fortitude Family Office’s Vor Biopharma VOR Stock Holding History

Fortitude Family Office’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-31	Closed	-$553	–	2385
2026 Q1	$553	Buy	+31	New	+$437	﹤0.01%	1689

Other funds holding VOR

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Fortitude Family Office's VOR Position: Q2 2026 in Review

Fortitude Family Office sold out of Vor Biopharma (VOR) in Q2 2026, closing a stake of 31 shares — an estimated $553 sold.

Fortitude Family Office first reported a position in VOR in Q1 2026 and held it in 1 quarter. The position peaked at $553 in Q1 2026. 7 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

Fortitude Family Office reported no remaining Vor Biopharma position as of Q2 2026 after selling out during the quarter.
Fortitude Family Office sold 31 Vor Biopharma shares in Q2 2026, an estimated $553.
Fortitude Family Office first reported a position in Vor Biopharma in Q1 2026 and held it in 1 quarter.
Fortitude Family Office's Vor Biopharma position peaked at $553 in Q1 2026.
7 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.